Pfizer’s COVID-19 vaccine trial data shows long-term efficacy in adolescents
FILE PHOTO: Registered nurse Sheba Phillip administers a dose of the Pfizer-BioNTech vaccine for the coronavirus disease (COVID-19) to 14-year-old Angel Rodriguez, during a vaccination event for local adolescents and adults outside the Bronx Writing Academy school in the Bronx borough of New York City, New York, U.S., June 4, 2021. REUTERS/Mike Segar
Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15.
A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.
The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.
Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.
The vaccine was authorized for emergency use in people 12 to 15 years old by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.
For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this
